Clinical Trial Update: Dabrafenib and/or Trametinib Rollover Study [Phase 4]

View source ↗

Summary

Phase 4 rollover study of dabrafenib and/or trametinib for melanoma and non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma, Non Small Cell Lung Cancer | Phase 4 | Status: RECRUITING